Upload
adi-zamir
View
75
Download
0
Embed Size (px)
Citation preview
Improving Early Detecti on of Melanoma
By Emerald Medical Applications
2
Forward Looking Statements
The Company believes that some of the statements included in this release may
constitute "forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as
that term is defined in the Private Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive factors,
technological development, market demand and the Company’s ability to obtain
contracts and accurately estimate net revenues due to variability in size, scope and
duration of contracts. Further information on potential factors that could affect the
Company’s financial results, can be found in the Company’s various filings with the
Securities and Exchange Commission (SEC).
3
Emerald Medical Applications
Startup nation spirit
Project launch 2013
16 Team members Edge of technology
260 years - vast experience
CEO – Lior Wayn VP Product – Adi Zamir VP R&D Itzik Hanan CFO – Oded Gilboa
4
R&D project with an EU partners
3rd place!!!
Awards
5
6
Market$25 B
Cost of treatmentUSA
5 M treated, $8 B in treatment cost / year
UK$600 M treatment
cost / year
Germany“Skin Cancer is the
nation’s most common cancer”
420 M People at high risk of Melanoma$150,000 per patient - Direct costs for the
treatment
Australia1 of 7
7
SolutionEmerald Derma Compare
EDC
8
……. For saving lives !!!
N1 (x, y, z,…)
N1 (x, y, z,…)
9
It’s all about comparison
1998 2008
2003 2012
2008 2014
TBP 2015 2016
10
SLR Camera MobileAPP Google Glass mHealth
Take a set of TBP photos
11
DermaCompare App
12
Doctor Clinique
13
Total body photography
Alert !
14
15
Crowd sourcing & Big data
16
Improving the Golden Standard
Supported by Chief Scientists
Multidimensional Database
Augmented Reality & Google Glass
Cloud SaaS
DermaCompare
Artificial Intelligence & Machine Learning
Automated Comparison
Tele medicine
17
SOLUTION – Key Benefits
01
Cloud / SaaS
02
Low cost
03
More accurate
04
Less overall costsof treatment
05
Serves morepatients
06
Higher turnoverfor physicians
18
Go to market
HMO’sClinics Hospitals InsuranceCompanies
PublicHealth
19
Business model
per patient
$95 Flat fee
Direct costs for the treatment-
$150,000
Per patient per year
20
Emerald’s journey
2013
BootstrappingAnd POCs
2014
Doctor Module
11/2014
Investment & Public
03/2015
03/2015
G2M in Germany
Mobile APP
21
Going Public
Emerald signed a share exchange agreement
with Zaxis international Inc ( OTCQB : ZXSI)
that will result in Emerald becoming Zaxis's
fully owned subsidiary.
The reverse merger is expected to be completed
within
60-90 days
22
Early Detection of skin Cancer
ABCof saving lives!!
23
Lior Wayn – CEO Adi Zamir- VP
Skype: LiorWayn Adi_Zamir
[email protected] [email protected]
+972-50-6816300 +972-54-4861247
www.facebook.com/EmeraldDC